AMENDMENT TRANSMITTAL LETTER (Large Entity) Applicant(s): Campbell et al.						Docket No. PG3602USW	
Serial No. 09/830,836		Filing Date May 1, 2001		Examiner B. Robinson		Group Art Unit 1625	
Invention: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS							
TO THE ASSISTANT COMMISSIONER FOR PATENTS: Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.							
CLAIMS AS AMENDED							
	CLAIMS REMAINING	HIGHEST #		PRESENT	RATE	ADDITIONAL	
TOTAL CLAIMS	AFTER AMENDMENT 20 -	PREV. PAID FOR		0)	x \$18.		
INDEP. CLAIMS	5 -	5 =	,	0 ;	·		
Multiple Dependent Claims (check if applicable)						\$0.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT \$0.00							
No additional fee is required for amendment. Please charge Deposit Account No. in the amount of A duplicate copy of this sheet is enclosed. A check in the amount of to cover the filling fee is enclosed. The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392 A duplicate copy of this sheet is enclosed. Any additional filling fees required under 37 C.F.R. 1.16. Any patent application processing fees under 37 CFR 1.17. Dated: // Sup 2002 Lorie Ann Morgan, Reg. No. 38,181 Attorney for Applicants GlaxoSmith Kline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-8222 Facsimile: (919) 483-7988							

PTC/SB/97 (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8


I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office


Allyson K. Jacobs

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.







NO. 5903 P. 8 10/23/07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application:

1. Campbell et al.,

Serial No.:

09/830,836

Examiner:

B. Robinson

Filing Date:

1 May 2001

Art Unit:

1625

For:

PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

Commissioner of Patents Washington D.C. 20231

SUPPLEMENTAL RESPONSE

Sir:

Further to the Office Action mailed 15 May 2002 and the response filed 13 August 2002, please amend and reconsider the instant application in view of the following amendments and remarks.

In the Claims:

Amendmen

Please cancel claims 13 and 24. Please amend claims 1, 6, 8-10, 14, 18-23, 25-26 and 28-29 as follows. The following clean claims reflect the amendments being made herein. The following is a complete set of claims as pending after the instant amendment. A marked-up copy of the amended claims is attached hereto.